Skip to main content
. 2020 Apr 14;11(6):1578–1586. doi: 10.1111/1759-7714.13432

Figure 1.

Figure 1

Kaplan‐Meier curves according to the lung immune prognostic index (LIPI) in small cell lung cancer (SCLC) patients. (a) The median progression‐free survival (PFS) of the LIPI 0 group was significantly longer than that of the LIPI 1 plus 2 group (7.6 months vs. 5.6 months, respectively, P = 0.020) (Inline graphic ) LIPI 0 group, (Inline graphic ) LIPI 1 plus 2 group. (b) The median overall survival (OS) of the LIPI 0 group was significantly longer than that of the LIPI 1 plus 2 group (21.0 months vs. 11.6 months, respectively, P < 0.001) (Inline graphic ) LIPI 0 group, (Inline graphic ) LIPI 1 plus 2 group.